Veracyte Stock Surges After Strong First-Quarter Earnings and Growth Outlook
Shares of Veracyte (NASDAQ: VCYT) rose by 23% over the past week following strong first-quarter results, including a 21% revenue increase and quadrupled earnings per share. The company's main products for prostate and thyroid cancer detection saw double-digit sales growth, while new tests in development are expected to drive further expansion.
Tickers: $VCYT
Topics: biotechnology diagnostics finance healthcare